Endo Strikes Mylan With Suit Over Generic Frova
Endo claims Mylan's Frova generic would infringe three of its patents issued between 1995 and 1998 that cover frovatriptan tablets.
Mylan notified the Pennsylvania-based pharmaceutical company on July 1 that it had submitted an abbreviated new drug application with the U.S. Food and Drug Administration for 2.5-milligram base tablets of frovatriptan succinate EQ.
Mylan says in a statement that...
To view the full article, register now.